Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 17;398(10296):207-209.
doi: 10.1016/S0140-6736(21)01462-8. Epub 2021 Jun 28.

AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC

Emma C Wall  1 , Mary Wu  2 , Ruth Harvey  2 , Gavin Kelly  2 , Scott Warchal  2 , Chelsea Sawyer  2 , Rodney Daniels  2 , Lorin Adams  2 , Philip Hobson  2 , Emine Hatipoglu  3 , Yenting Ngai  3 , Saira Hussain  2 , Karen Ambrose  2 , Steve Hindmarsh  2 , Rupert Beale  4 , Andrew Riddell  2 , Steve Gamblin  2 , Michael Howell  2 , George Kassiotis  5 , Vincenzo Libri  6 , Bryan Williams  6 , Charles Swanton  7 , Sonia Gandhi  7 , David Lv Bauer  8
Affiliations

AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC

Emma C Wall et al. Lancet. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

CSw reports grants from BMS, Ono-Pharmaceuticals, BoehringerIngelheim, Roche-Ventana, Pfizer, and Archer Dx, unrelated to this Correspondence; personal fees from Genentech, Sarah Canon Research Institute, Medicxi, Bicycle Therapeutics, GRAIL, Amgen, AstraZeneca, BMS, Illumina, GlaxoSmithKline, MSD, and Roche-Ventana, unrelated to this Correspondence; and stock options from Apogen Biotech, Epic Biosciences, GRAIL, and Achilles Therapeutics, unrelated to this Correspondence. All other authors declare no competing interests. ECW, MW, and RH contributed equally. GKa, CSw, SGan, and DLVB are joint senior authors. RB and DLVB are members of the Genotype-to-Phenotype UK National Virology Consortium. Funding details and acknowledgments can be found in the appendix All data (anonymised) and full R code to produce all figures and statistical analysis presented in this Correspondence are available online on GitHub.

References

    1. Public Health England SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 16. June 18, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploa...
    1. Department of Health and Social Care and Scientific Advisory Group for Emergencies The R value and growth rate. June 18, 2021. https://www.gov.uk/guidance/the-r-value-and-growth-rate
    1. Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021;397:2331–2333. - PMC - PubMed
    1. Stamatatos L, Czartoski J, Wan Y-H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021 doi: 10.1126/science.abg9175. published online March 25. - DOI - PMC - PubMed
    1. Reynolds CJ, Pade C, Gibbons JM, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 2021 doi: 10.1126/science.abh1282. published online April 30. - DOI - PMC - PubMed

Uncited References

    1. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478. - PMC - PubMed

Publication types